AU2021293021A1 - Compositions and methods for treating late-onset pompe disease - Google Patents

Compositions and methods for treating late-onset pompe disease Download PDF

Info

Publication number
AU2021293021A1
AU2021293021A1 AU2021293021A AU2021293021A AU2021293021A1 AU 2021293021 A1 AU2021293021 A1 AU 2021293021A1 AU 2021293021 A AU2021293021 A AU 2021293021A AU 2021293021 A AU2021293021 A AU 2021293021A AU 2021293021 A1 AU2021293021 A1 AU 2021293021A1
Authority
AU
Australia
Prior art keywords
individual
treatment
pharmaceutical composition
score
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021293021A
Other languages
English (en)
Inventor
Kristina AN HAACK
Patrick Finn
Alaa HAMED
Catherine Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AU2021293021A1 publication Critical patent/AU2021293021A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021293021A 2020-06-14 2021-06-11 Compositions and methods for treating late-onset pompe disease Pending AU2021293021A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063038857P 2020-06-14 2020-06-14
US63/038,857 2020-06-14
US202063076037P 2020-09-09 2020-09-09
US63/076,037 2020-09-09
US202163147629P 2021-02-09 2021-02-09
US63/147,629 2021-02-09
US202163157490P 2021-03-05 2021-03-05
US63/157,490 2021-03-05
PCT/US2021/037111 WO2021257409A1 (en) 2020-06-14 2021-06-11 Compositions and methods for treating late-onset pompe disease

Publications (1)

Publication Number Publication Date
AU2021293021A1 true AU2021293021A1 (en) 2023-02-23

Family

ID=76797137

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021293021A Pending AU2021293021A1 (en) 2020-06-14 2021-06-11 Compositions and methods for treating late-onset pompe disease

Country Status (13)

Country Link
US (2) US12533396B2 (enExample)
EP (1) EP4164678A1 (enExample)
JP (2) JP2023530112A (enExample)
KR (1) KR20230025874A (enExample)
CN (1) CN115916245A (enExample)
AU (1) AU2021293021A1 (enExample)
BR (1) BR112022025314A2 (enExample)
CA (1) CA3182409A1 (enExample)
IL (1) IL299015A (enExample)
MX (1) MX2022016019A (enExample)
TW (1) TW202214302A (enExample)
WO (1) WO2021257409A1 (enExample)
ZA (1) ZA202300544B (enExample)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP5137814B2 (ja) 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート
CN102978185B (zh) 2007-01-18 2015-02-11 建新公司 包含氨基氧基基团的寡糖及其轭合物
EP3608330B1 (en) * 2008-12-16 2022-11-09 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
IL299470B2 (en) 2015-12-30 2026-05-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
EP4100120A1 (en) 2020-02-08 2022-12-14 Genzyme Corporation Compositions and methods for treating pompe disease

Also Published As

Publication number Publication date
WO2021257409A1 (en) 2021-12-23
US12533396B2 (en) 2026-01-27
US20230256062A1 (en) 2023-08-17
EP4164678A1 (en) 2023-04-19
JP2026117025A (ja) 2026-07-14
IL299015A (en) 2023-02-01
KR20230025874A (ko) 2023-02-23
BR112022025314A2 (pt) 2023-01-03
MX2022016019A (es) 2023-04-10
TW202214302A (zh) 2022-04-16
JP2023530112A (ja) 2023-07-13
CA3182409A1 (en) 2021-12-23
CN115916245A (zh) 2023-04-04
US20260216302A1 (en) 2026-07-30
ZA202300544B (en) 2026-02-25

Similar Documents

Publication Publication Date Title
US20250057925A1 (en) Recombinant Human Acid Alpha-Glucosidase
EP2844279B1 (en) Dosing regimens for the treatment of pompe disease
EP4029498B1 (en) Bis-choline tetrathiomolybdate for treating wilson disease
JP2020203886A (ja) 腎機能障害を有するファブリー患者の治療方法
US20190240292A1 (en) Methods of administering hepcidin
US20250319166A1 (en) Compositions and methods for treating pompe disease
US20100143321A1 (en) Therapeutic composition for interstitual pneumonia
EP4164678A1 (en) Compositions and methods for treating late-onset pompe disease
US20240016879A1 (en) Copper complexes for treatment of neurodegenerative disorders
JP2025540135A (ja) 小児患者の乳児発症型ポンペ病の治療方法
RU2861586C2 (ru) Композиции и способы лечения болезни помпе с поздним началом
RU2850019C1 (ru) Композиции и способы для лечения болезни помпе
EP3315128B1 (en) Dosing regimen of rovatirelin for ataxia associated with spinocerebellar degeneration
HK40117702A (en) Liquid botulinum toxin composition for treating moderate to very severe glabellar lines and lateral canthal lines
HK40026823A (en) Recombinant human acid alpha-glucosidase
HK40026823B (en) Recombinant human acid alpha-glucosidase
HK1263071A1 (en) Methods of administering hepcidin
EA045409B1 (ru) Рекомбинантная человеческая кислая альфа-глюкозидаза